

Special Issue

Vaccination Coverage and Vaccine Hesitancy

Message from the Guest Editors

Dear colleagues, Vaccination represents an effective approach to prevent life-threatening illness/death from infectious agents and infection-related carcinogenesis. In addition, successful vaccination programs with high vaccination coverage may narrow the transmission of pathogens, as well as offer protection to vulnerable subjects that are not suitable candidates for vaccination. Thus, vaccines are key determinants of social and economic benefits in terms of healthcare system resilience, life expectancy, community interaction opportunities and productivity. However, health inequities, age-related differences in vaccine efficacy and a lack of capillary information represent some of the most prominent obstacles towards global immunization against vaccine-preventable diseases. The purpose of this Special Issue is to discuss the relevance and challenges of vaccination in the light of health policies, and possible strategies to overcome vaccine hesitancy and inequalities in vaccine availability/distribution.

Guest Editors

Dr. Fanny Pojero

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, 90123 Palermo, Italy

Dr. Mario Allegra

Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Università degli Studi di Palermo, 90123 Palermo, Italy

Deadline for manuscript submissions

closed (31 March 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/159093

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).